Welcome to Moberg Pharma – a different kind of pharmaceutical company.

When we started Moberg Pharma in 2006 our objective was to launch our first products on the market within 3-5 years. After four years – during autumn 2010 - Nalox was launched in the first markets - a significant milestone for the company.

Our business model provides a higher probability of reaching the market, lower investments and shorter development time compared to traditional drug development. This is because we focus on improved topical drugs based on proven substances.

Our objective is to develop Moberg Pharma into a profitable pharmaceutical company that regularly delivers new topical drugs to a global market. The acquisition of Moberg Pharma North America (former Alterna) during the fall of 2012 has provided us with a platform for continued growth through an established and proven organization for marketing of OTC drugs and self-care products in the U.S.

I am convinced that our approach is a key factor for success. We are a small and efficient team with high management capacity. Through close collaboration with external partners and experts we leverage the resources invested. We combine business acumen with expertise of drug development, and have a business and marketing team experienced in global commercialisation of products. We put a lot of energy into the marketing work together with our partners, in order to ensure market success.

We have received fantastic support from our owners throughout, and I welcome new owners to Moberg Pharma. I am convinced that our model facilitates development of a profitable company that will benefit patients, employees and owners. Please get in touch with me if you have any questions or are interested in Moberg Pharma.

Peter Wolpert
CEO and founder

Business concept

Moberg Pharma's business concept is to develop patented topical drugs for treatment of common disorders through use of innovative drug-delivery technology. The company's products are based on proven compounds, thus reducing time to market, development costs and risk.

 site policy

© Moberg Pharma AB 2013